Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
Completed
Eisai Co., Ltd.
2015-05-20
This study is a post-marketing surveillance of lenvatinib in participants with unresectable
thyroid cancer. The objectives of this study are to capture unknown adverse reactions,
incidences of adverse drug reaction, efficacy, factors considered to have effect to safety
and effectiveness, and incidences of hypertension, hemorrhagic events and thromboembolic
event, and liver disorder.
Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Active, not recruiting
Merck Sharp & Dohme Corp.
Phase 1/Phase 2
2015-07-22
This is an open-label Phase 1b/2 trial of lenvatinib (E7080) plus pembrolizumab in
participants with selected solid tumors. Phase 1b will determine and confirm the maximum
tolerated dose (MTD) for lenvatinib in combination with 200 milligrams (mg) (intravenous
[IV], every 3 weeks [Q3W]) pembrolizumab in participants with selected solid tumors (i.e.
non-small cell lung cancer, renal cell carcinoma, endometrial carcinoma, urothelial
carcinoma, squamous cell carcinoma of the head and neck, or melanoma). Phase 2 (Expansion)
will evaluate the safety and efficacy of the combination in 6 cohorts at the MTD from Phase
1b (lenvatinib 20 mg/day orally + pembrolizumab 200 mg Q3W, IV).
Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Active, not recruiting
Eisai Inc.
Phase 1/Phase 2
2015-07-22
This is an open-label Phase 1b/2 trial of lenvatinib (E7080) plus pembrolizumab in
participants with selected solid tumors. Phase 1b will determine and confirm the maximum
tolerated dose (MTD) for lenvatinib in combination with 200 milligrams (mg) (intravenous
[IV], every 3 weeks [Q3W]) pembrolizumab in participants with selected solid tumors (i.e.
non-small cell lung cancer, renal cell carcinoma, endometrial carcinoma, urothelial
carcinoma, squamous cell carcinoma of the head and neck, or melanoma). Phase 2 (Expansion)
will evaluate the safety and efficacy of the combination in 6 cohorts at the MTD from Phase
1b (lenvatinib 20 mg/day orally + pembrolizumab 200 mg Q3W, IV).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
